Daratumumab, a monoclonal antibody targeting CD38, has shown promising preclinical and early clinical activity in pediatric hematologic malignancies, including T-ALL and lymphoblastic lymphoma. This evidence concerns the gene CD38 and acute lymphoblastic leukemia.